{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-036093","form_type":"8-K/A","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.154103+00:00","generated_at":"2026-06-23T05:43:42.381315+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lisata provides financials of acquired Cend; CEND-1 in Phase 2b for pancreatic cancer","bullets":["Merger of Cend into Lisata completed Sep 14, 2022; this amendment provides historical and pro forma financials of Cend.","Cend's lead drug CEND-1 (iRGD peptide) in Phase 2b for 1L metastatic PDAC; Phase 1b showed promising safety and efficacy.","Cend collaboration with Qilu Pharma for Greater China: $10M upfront, up to $225M in milestones, tiered royalties 10-15%.","Cend recorded net income in 2021 from one-time license payment, but otherwise incurred losses since inception.","Unaudited interim financials of Cend as of June 30, 2022 and pro forma combined financials of Lisata are filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-036093","json":"https://secwatch.observer/filing/0001140361-22-036093.json","markdown":"https://secwatch.observer/filing/0001140361-22-036093.md","text":"https://secwatch.observer/filing/0001140361-22-036093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/0001140361-22-036093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/brhc10042374_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:43:42.381315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}